6 recruiting, 5 unknown, 3 completed, 3 not yet recruiting. 13 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 5, Unknown 4, Completed 3, Not yet recruiting 1 |
| Phase 3 | 5 | Not yet recruiting 2, Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
Follow Tislelizumab Injection: new trials by email Literature Review of Tislelizumab Injection trials Research Report on Tislelizumab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） SYS6010 injection, Enlonstobart injection, Tislelizumab injection - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 500 | 2026-06-02 | 2026-06-11 |
| A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] LBL-024 for Injection, Capecitabine tablets, Tislelizumab Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 110 | 2026-04-13 | 2026-05-13 |
| A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 110 | 2026-02-26 | 2026-05-18 |
| An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer Tislelizumab Injection - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Sichuan University | 21 | 2025-10-01 | 2025-03-19 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC JSKN016, Carboplatin, Furmonertinib Mesylate - Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 288 | 2025-04-02 | 2026-03-30 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC Anlotinib Hydrochloride Capsule, Tislelizumab Injection, Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Ji Yongling | 20 | 2024-05-01 | 2025-07-10 |
| IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors MSC-IFNα, Nab paclitaxel, Cyclophosphamide - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 40 | 2023-02-23 | 2023-04-28 |
| TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection - Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 570 | 2023-02-01 | 2023-02-14 |
| Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy - Urinary Bladder Neoplasms | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 65 | 2023-02-01 | 2022-12-28 |
| PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma Tislelizumab Injection - Advanced Melanoma | Phase 2 | Unknown | Henan Cancer Hospital | 40 | 2022-12-30 | 2023-10-24 |
| Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer Arterial chemoembolization, Tislelizumab Injection, XELOX - Rectal Neoplasms | Phase 2 | Unknown | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 83 | 2022-11-29 | 2023-05-11 |
| A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection - Malignant Tumors | Phase 1 / Phase 2 | Completed | Nanjing Leads Biolabs Co.,Ltd | 98 | 2022-09-01 | 2026-04-01 |
| Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC Tislelizumab, Ablation - Recurrent Hepatocellular Carcinoma | Phase 2 | Unknown | Ming Zhao | 120 | 2020-12-21 | 2023-03-22 |
| Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules Tislelizumab Injection - Multiple Pulmonary Nodules | Phase 2 | Completed | XiangNing Fu | 12 | 2019-07-01 | 2025-09-23 |
| Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemotherapy/targeting - Advanced Solid Tumor | Phase 2 / Phase 3 | Completed | Beijing Friendship Hospital | 172 | 2019-05-01 | 2023-04-12 |
Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (2) · Carcinoma, Hepatocellular (1) · Multiple Pulmonary Nodules (1) · Neoplasms (1) · Rectal Neoplasms (1) · Urinary Bladder Neoplasms (1)
Nanjing Leads Biolabs Co.,Ltd (3) · Beijing Friendship Hospital (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's Cancer Group, China (1) · Chinese PLA General Hospital (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Henan Cancer Hospital (1) · Ji Yongling (1) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd (1) · Ming Zhao (1) · Sichuan University (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (1) · XiangNing Fu (1)
China (15)
Lin Shen (2) · Jinhai Fan, MD (1) · Li Zhang (1) · Ming Zhao, MD (1) · WeiDong Han, PhD (1) · YongLing Ji, PhD (1) · Yongsheng Wang (1) · Yufang Shi, PhD (1)